Product image of Ipratropiumbromide/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate) supplied by GNH India

Ipratropiumbromide/Salbutamol Cipla

Active Ingredient:
Salbutamol, Ipratropium Bromide Monohydrate
Origin:
EU

Ipratropiumbromide/Salbutamol Cipla (Salbutamol, Ipratropium Bromide Monohydrate)

Ipratropium bromide, the active ingredient in Ipratropiumbromide/Salbutamol Cipla, is a bronchodilator presented as a combination inhalation solution for inhalation use. It treats bronchospasm associated with COPD, asthma and acute episodes in adult patients.

GNH India supplies Ipratropiumbromide/Salbutamol Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Cipla Europe Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ipratropiumbromide/Salbutamol is indicated for respiratory conditions where bronchodilation is required.
  • Bronchospasm associated with chronic obstructive pulmonary disease (COPD): provides rapid relief of airflow limitation.
  • Asthma: improves bronchial tone during acute episodes.
  • Acute bronchospasm: delivers fast‑acting bronchodilation to restore ventilation.

How It Works

  • Ipratropium bromide acts as an anticholinergic agent by blocking muscarinic receptors on airway smooth muscle, preventing acetylcholine‑mediated bronchoconstriction. Salbutamol is a short‑acting β2‑adrenergic agonist that stimulates β2 receptors, increasing cyclic AMP and causing relaxation of bronchial smooth muscle. The combined action produces additive bronchodilation, improving airflow in obstructive airway diseases.

Side Effects

The combination may cause a range of adverse reactions, which are classified by frequency.

Common Side Effects

  • Tremor: mild shaking of the hands or limbs.
  • Headache: transient pain in the head region.
  • Throat irritation: discomfort or soreness after inhalation.
  • Cough: brief episodes of coughing post‑dose.
  • Palpitations: sensation of rapid or irregular heartbeat.
  • Dry mouth: reduced salivation leading to oral dryness.

Serious or Rare Side Effects

  • Paradoxical bronchospasm: worsening of breathing difficulty after use.
  • Tachycardia or arrhythmia: significant increase in heart rate or irregular rhythm.
  • Angioedema: swelling of face, lips, tongue or airway.
  • Severe allergic reaction: rash, hives, or anaphylaxis.
  • Hyperglycaemia: elevated blood glucose levels, especially in diabetic patients.

Precautions & Warnings

  • Before prescribing Ipratropiumbromide/Salbutamol, clinicians should consider several safety measures.
  • Cardiac assessment: evaluate for arrhythmias or tachycardia risk.
  • Paradoxical bronchospasm: monitor for worsening breathing after initial dose.
  • Glaucoma: use with caution in patients with narrow‑angle glaucoma.
  • Hypersensitivity: avoid in individuals with known allergy to anticholinergics or β2‑agonists.
  • Renal/hepatic impairment: adjust monitoring in severe dysfunction.
  • Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Ipratropiumbromide/Salbutamol can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Beta‑blockers: may diminish bronchodilator effect.
  • MAO inhibitors: increased risk of cardiovascular events.
  • Tricyclic antidepressants: potential for enhanced tachycardia.
  • Diuretics: may exacerbate hypokalaemia.
  • Other anticholinergics: additive anticholinergic load.

Moderate Interactions (Monitor Closely)

  • Theophylline: additive bronchodilation, monitor serum levels.
  • Inhaled corticosteroids: may increase overall bronchodilator response.
  • Diabetes medications: monitor blood glucose as β2‑agonists can raise glucose.
  • Antihistamines: may increase dry‑mouth sensation.
  • ACE inhibitors: observe for cough or bronchospasm augmentation.

Frequently Asked Questions

Ipratropiumbromide/Salbutamol Cipla is a prescription inhalation product used to relieve bronchospasm in chronic obstructive pulmonary disease (COPD), asthma and acute bronchospasm episodes. It provides rapid bronchodilation by combining an anticholinergic and a short‑acting β2‑agonist.

Ipratropium bromide blocks muscarinic receptors on airway smooth muscle, preventing acetylcholine‑induced constriction. When combined with salbutamol, which stimulates β2‑adrenergic receptors to relax smooth muscle, the two agents produce additive bronchodilation, improving airflow more effectively than either component alone.

The dose is individualized and set by the prescribing healthcare professional based on the patient’s condition, severity of symptoms and response to therapy. Patients should follow the prescriber’s instructions and the product’s labeling for the correct inhalation technique and frequency.

The pregnancy category for this combination is listed as unknown. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their physician.

Enquiries can be submitted on the product page at gnhindia.com by specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Albuterol (salbutamol) alone provides β2‑agonist‑mediated bronchodilation, while the combination adds ipratropium’s anticholinergic effect. The dual mechanism often results in greater and longer‑lasting airway opening, especially in patients with severe COPD or those who experience suboptimal response to a single agent.

Store the inhalation solution at ambient temperature, below 25 °C, in its original container. Protect it from moisture, direct sunlight and extreme temperatures. Keep the vial tightly sealed when not in use to maintain sterility and potency.

The product is intended for inhalation, typically via a nebulizer or a metered‑dose inhaler as directed by the prescriber. Patients should use the device according to the manufacturer’s instructions, ensuring proper mouth‑piece placement and breath coordination to achieve optimal drug delivery.

Serious adverse events include paradoxical bronchospasm, significant tachycardia or arrhythmia, angioedema, severe allergic reactions (anaphylaxis) and hyperglycaemia in susceptible individuals. Any sudden worsening of breathing, rapid heartbeat, swelling of the face or throat, or signs of an allergic reaction require immediate medical attention.

Patients with known hypersensitivity to ipratropium, salbutamol or any excipients in the formulation should avoid this product. It is also contraindicated in individuals with narrow‑angle glaucoma or urinary retention where anticholinergic effects may exacerbate the condition.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Salbutamol, Ipratropium Bromide Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT